Results for oncology translation from Danish to English

2) – addendum on paediatric oncology.
points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome

baxter oncology gmbh kantstraße 2 d- 33790 halle tyskland
baxter oncology gmbh kantstraße 2 d-33790 halle germany

baxter oncology gmbh kantstrasse 2 33790 halle/ westfalen tyskland
baxter oncology gmbh kantstrasse 2 33790 halle/westfalen germany

fremstilleren baxter oncology gmbh, kantstraße 2, 33790 halle, tyskland
manufacturerbaxter oncology gmbh, kantstrasse 2, d-33790 halle, germany.

fremstiller baxter oncology gmbh kantstrasse 2 33790 halle/westfalen tyskland
manufacturer baxter oncology gmbh kantstrasse 2 33790 halle/westfalen germany

ldh: laktatdehydrogenase, ecog-ps: eastern oncology group performance status
ldh: lactate dehydrogenase, ecog ps: eastern cooperative oncology group performance status

kun patienter, som havde eastern cooperative oncology group (ecog)-performancestatus 0 eller 1 kunne deltage.
only patients with eastern cooperative oncology group (ecog) performance status 0 or 1 were eligible.

fremstiller baxter oncology gmbh kantstrasse 2 33790 halle/ westfalen tyskland eller catalent uk packaging limited sedge close headway great oakley corby northamptonshire nn18 8hs storbritannien
26 or catalent uk packaging limited sedge close headway great oakley corby northamptonshire nn18 8hs united kingdom

tumorer skulle være målelige i mindst et sygdomsområde og responskarakterisering baseret på swog-kriterier (southwestern oncology group).
tumours were required to be measurable in at least one site of disease, and response characterisation based on southwestern oncology group (swog) criteria.

fremstilleren baxter oncology gmbh, kantstraße 2, 33790 halle, tysklandfor yderligere oplysninger om dette lægemiddel bedes henvendelse rettet til den lokale repræsentant for indehaveren af markedsføringstilladelsen.
manufacturerbaxter oncology gmbh, kantstrasse 2, d-33790 halle, germany. for any information about this medicinal product, please contact the local representative of the marketing authorisation holder.

alle patienter, der var inkluderet i dette studie havde en ecog (eastern cooperative oncology group) performance-status på 0 eller 1.
all patients included in this study had an ecog performance status 0 or 1.

ecog: eastern cooperative oncology group, bpi-sf: brief pain inventory-short form, psa: prostataspecifikt antigen
ecog: eastern cooperative oncology group; bpi-sf: brief pain inventory-short form; psa: prostate specific antigen

ecog-(eastern cooperative oncology group)-performance-status var næsten ens for begge grupper, hvilket også gjaldt for antallet og typen af tidligere behandlinger.
the ecog performance status was comparable between both groups, as was the number and type of prior therapies.

patienter med en eastern cooperative oncology group (ecog) performancestatus på 0 til 2 blev inkluderet i studiet, og 91 % havde en ecog-performancestatus på 0 eller 1.
patients with an eastern cooperative oncology group (ecog) performance status of 0 to 2 were enrolled into the study and 91% had an ecog performance status of 0 or 1.

i et randomiseret, sammenlignende fase iii-studie, udført af gynaecological oncology group (gog 0179), blev topotecan + cisplatin (n = 147) sammenlignet med cisplatin alene (n = 146) for behandling af histologisk bekræftet, persisterende, recidiverende eller stadium ivb-cervixcancer, hvor kurativ intenderet behandling med kirurgi og/eller stråleterapi ikke var vurderet hensigtsmæssig.
in a randomised, comparative phase iii trial conducted by the gynaecological oncology group (gog 0179), topotecan plus cisplatin (n = 147) was compared with cisplatin alone (n = 146) for the treatment of histologically confirmed persistent, recurrent or stage ivb carcinoma of the cervix where curative treatment with surgery and/or radiation was not considered appropriate.